The HPV Vaccine What the Research Actually Reveals
HPV infection and HPV-associated cervical cancer are significant national and global public health concerns. An estimated 11,000 newly diagnosed cases of cervical cancer occur annually in the United States, resulting in 3700 deaths.
Globally, an estimated 493,000 new cervical cancer cases occur each year, with 274,000 deaths; more than 80% of cervical cancer deaths worldwide occur in developing countries.
Human papillomavirus is the most common sexually transmitted infection in the United States, with an estimated 6.2 million individuals newly infected annually
WHAT IS THE HPV VACCINE?
The HPV vaccine claims to protect against some types of the human papillomavirus (HPV) that can cause cervical cancer and genital warts. Two HPV vaccines are available: HPV4 and HPV2.
The ingredients are proteins of HPV Types 6, 11, 16, and 18, amorphous aluminum hydroxyphosphate sulfate, yeast protein, sodium chloride, L-histidine, polysorbate 80, sodium borate, and water for injection.
The Federal Advisory Committee on Immunization Practice recommends that all girls age 11 thru 12years old should get vaccinated against HPV. Health care providers may also give the vaccine to girls as young as 9 years, and to girls and women aged 13 thru 26 years who haven’t gotten the vaccine yet. One of the HPV vaccines is also licensed for boys and men ages 9 thru 26 years to prevent genital warts.
There are two licensed HPV vaccines, Gardasil®, manufactured by Merck and Cervarix®, manufactured by GlaxoSmithKline . Gardasil® was licensed for use in females, age 9-26 years in June 2006 and for males’ age 9-26 years in Oct 2009. Cervarix® was licensed for use in females age 10-25 in October 2009.
IS A VACCINE EVEN NECESSARY?
The first problem with using a vaccine approach is that there are over one hundred known strains of HPV, (and likely hundreds if not thousands of unknown strains) only 30 of which are even theoretically linked with cervical cancer. In addition, HPV is present in at least half the normal population, almost never causing any disease or problems whatsoever.
Numerous studies have shown 70 to 90 percent of people with HPV naturally clear the virus from the body within two years of infection — with no help from drugs or vaccines. So the most effective protection from problems caused by HPV is to avoid being infected by the multiple strains of HPV by not engaging in promiscuous, unprotected-by- condoms sex (the virus is transmitted sexually and condoms do not offer 100 percent protection) and by keeping your body’s immune system strong and healthy through natural health practices.
HPV has never been scientifically proven to be a pathogen for cervical cancer
All that has ever been shown is that HPV is sometimes present in cervical cancer tissue, but as we know it's also present in half the normal population. There is a complete lack of evidence that cervical cancer appears in women with HPV more often than in women without it. And yet this will be the primary objective of the vaccine: to pretend to eliminate this ubiquitous virus from the body. The original phrase used by Merck to link HPV with cervical cancer was "there is a strong connection." How that phrase got transformed to 'is the cause of' in the past two years is more a matter of shrewd marketing than of quality science.
The second obstacle to credibility with the HPV vaccine is that the average age for cervical cancer is 50 years. But the plan is to mandate the HPV vaccine to girls as young as 11 years of age and on certain occasions as young as 9 years of age. And the manufacturer is only claiming efficacy for 5 years.
So using their own statistics, this makes the vaccine worthless in the long run, because by the time most females need immunity, it will have worn off long ago.
QUALITY OF THE TEST STUDIES OF HPV
The FDA allowed Merck to use a potentially reactive aluminum containing placebo as a control for most trial participants, rather than a non-reactive saline solution placebo.
A reactive placebo can artificially increase the appearance of safety of an experimental drug or vaccine in a clinical trial.
For example, if we wanted to test the safety and efficacy of a carbonated soft drink on teeth, we would use water as a control or comparison. In the case of Merck clinical trials, they decided to use another soft-drink (which of course manipulated the data).
Gardasil contains 225 mcg of aluminum and, although aluminum adjuvants have been used in vaccines for decades, they were never tested for safety in clinical trials. Merck and the FDA did not disclose how much aluminum was in the placebo.
Here's what is alarming
Almost 90% of Gardasil recipients and 85% of aluminum placebo recipients followed-up for safety reported one or more adverse events within 15 days of vaccination. In addition, pain and swelling at the injection site occurred in approximately 83% of Gardasil and 73% of aluminum placebo recipients. Sixty percent of those who got Gardasil or the aluminum placebo had systemic adverse events including headache, fever, nausea, dizziness, vomiting, diarrhea, and myalgia.
The point here is that there is too little long term safety and effectiveness data to recommend Gardasil for universal use, especially mandatory use
ADVERSE REACTIONS TO THE HPV VACCINE
As of September 15, 2011, approximately 40 million doses of Gardasil® were distributed in the U.S. and VAERS (Vaccine Adverse Event Reporting System) received a total of 20,096 reports of adverse events following Gardasil® vaccination: 19,075 reports among females and 569 reports for males, of which 504 reports were received after the vaccine was licensed for males in October 2009. VAERS received 452 reports of unknown gender.
Adverse reactions that have been reported include:
- swelling at the injection site
- high fever
- blood clots
- muscle weakness
- Guillain-Barre Syndrome ( a neurological disorder that causes muscle weakness and atrophy)
As of September 15, 2011, there have been a total 71 VAERS reports of death among those who have received Gardasil®. There were 57 reports among females, 3 were among males, and 11 were reports of unknown gender or clustering to the deaths that would suggest that they were caused by the vaccine and some reports indicated a cause of death unrelated to vaccination.
Since licensed in October 2009, uptake of Cervarix® vaccination in the U.S. has been very low. As of September 2011, there have been 52 VAERS reports of adverse events following Cervarix®vaccination in the U.S.
It is important to note historically only a fraction of adverse events involving vaccines ever get reported and the longer the time between the administration of the vaccine and the adverse event occurring, the less likely it will be attributed to the initial administration. This means that the vast majority of damages caused by vaccines like HPV are never reported.
Even the Journal of the American Medical Association, normally a staunch defender of vaccines, has voiced its concern about a mandatory HPV vaccine.
The AMA Journal of American Medicine (JAMA) warns Legislators about mandatory HPV vaccine:
The HPV vaccine is supported by limited efficacy and safety data. Clinical trials have thus far involved a relatively small population for a limited period of follow- up (5 years). The vaccine has not been evaluated for efficacy among younger girls (aged 9 to 15 years). Yet, if the vaccine were required nationwide, it would be administered to some 2 million girls and young women, most of them between 11 and 12 years old and some as young as 9 years old. The longer-term effectiveness and safety of the vaccine still need to be evaluated among a large population, and particularly among younger girls. Given that the overall prevalence of HPV types associated with cervical cancer is relatively low (3.4%) and that the long-term effects are unknown, it is unwise to require a young girl with a very low lifetime risk of cervical cancer to be vaccinated.
“Merck has demonstrated that they are more than willing to gamble our children’s health on an unproven vaccine in return for immense profits. This magnitude of evil is rare, even for a drug company.”
Dr. Julian Whitaker
As of today, the Gardasil vaccine has never been proven to decrease the actual incidence of cervical cancer." In fact, according to the text Cancer: Principles & Practice of Oncology, "In most studies, HPV status was not a strong independent
prognosticator of outcome in cervical cancer patients; however there appears to be a trend for HPV-negative tumors to do worse …those tumors containing HPV DNA tend to be of an early stage and low grade." This suggests that if the goal is to
reduce deaths from cervical cancer the target should not be HPV at all because the tumors without HPV actually "do worse."
It is a frustrating time when our young girls and women are being lined up and jabbed with a vaccine that has the potential to affect their future fertility - and that may be the least of the problems.
Anyone with a HPV infection (and they are common), who is given the vaccine risks immune system shutdown or autoimmune disease.
They are not testing for wart virus infection prior to vaccination. In the trials for this vaccine they were careful to exclude anyone with a wart virus or who developed a wart virus infection.
They chose women who were not likely to have more than one sexual partner, thereby minimizing this risk.
THIS IS AN UNKNOWN RISK FACTOR but when you read the reports already in from overseas you will see that once again vaccination is not rocket science, unless you equate it with the ones that explode and obliterate!
Australian Immunization Council
The pharmaceutical-supported mainstream media, and the Merck- supported Public Broadcasting Service uncritically accept the claim that human papillomavirus is the cause of cervical cancer in women, despite the absence of supporting medical evidence.
There's also no discussion of the one pharmaceutical merchandise (i.e. feminine hygiene products) that is the most likely causes this cancer.
Director: Coalition for Informed Choice
REFERENCES AND RESOURCES
Mandic, A. and T. Vujkov. "Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?" Annals of Oncology, 15 (2), Feb 2004: 197-200.
Patel, D., et al. "Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up- regulation of G2-M-phase proteins." Cancer Research, 64(4), Feb 15 2004: 1299-306.
Kim, TW, et al. "Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity." Human Gene Therapy, 15(2), Feb 2004: 167-77.
Del Mistro, A, et al. "Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women." Clinical Infectious Disease, 38 (5), Mar 1 2004: 737-42.
Fridman, M, May, C. Saville, M, Reports of Health Concerns Following HPV Vaccination CDC October 24, 2011The Lancet, Volume 377, Issue 9783, Pages 2085 - 2092, 18 June 2011